First Rituxan biosimilar Truxima set to make its debut in USBiosimilar competition to Roche’s big-selling Rituxan has arrived in the US, with Teva gearing up to launch its Share XFirst Rituxan biosimilar Truxima set to make its debut in UShttps://pharmaphorum.com/news/first-rituxan-biosimilar-truxima-set-to-makes-its-debut-in-us/
Henlius Biotech shrugs off Hong Kong disruption with $477M IPO bidChina’s Henlius Biotech has pressed go on a $477 million initial public offering (IPO) on the Hong Kong Share XHenlius Biotech shrugs off Hong Kong disruption with $477M IPO bidhttps://pharmaphorum.com/news/henlius-biotech-shrugs-off-hong-kong-disruption-with-477m-ipo-bid/
Alexion’s biosimilar-blocking EU patent play for Soliris failsThe European Patent Office has blocked an attempt by Alexion to extend the patent protection for its blockbuster Share XAlexion’s biosimilar-blocking EU patent play for Soliris failshttps://pharmaphorum.com/news/alexions-biosimilar-blocking-eu-patent-play-for-soliris-fails/
Mylan’s Lantus biosimilar held up by manufacturing issueMylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient Share XMylan’s Lantus biosimilar held up by manufacturing issuehttps://pharmaphorum.com/news/mylans-lantus-biosimilar-held-up-by-manufacturing-issue/
Lilly faces biosimilar rivals to osteoporosis drug Forsteo in EuropeTwo biosimilars of Eli Lilly’s blockbuster osteoporosis treatment Forsteo – from Hungary’s Gedeon Richter and German partner Stada Share XLilly faces biosimilar rivals to osteoporosis drug Forsteo in Europehttps://pharmaphorum.com/news/lilly-faces-biosimilar-rivals-to-osteoporosis-drug-forsteo-in-europe/
J&J faces FTC probe on Remicade biosimilar defenceJohnson & Johnson’s antibody blockbuster Remicade has proved highly resistant to biosimilar competition – so much so that Share XJ&J faces FTC probe on Remicade biosimilar defencehttps://pharmaphorum.com/news/jj-faces-ftc-probe-on-remicade-biosimilar-defence/
Roche raises 2019 outlook, shrugging off biosimilar threatNew product sales helped Roche to a healthy 9% increase in sales in the first half of the Share XRoche raises 2019 outlook, shrugging off biosimilar threathttps://pharmaphorum.com/news/roche-raises-2019-outlook-shrugging-off-biosimilar-threat/
New deals extend Mundipharma biosimilar reachMundipharma has fleshed out its range of biosimilars by acquiring Tuznue, a version of Roche’s breast cancer blockbuster Share XNew deals extend Mundipharma biosimilar reachhttps://pharmaphorum.com/news-market-access/new-deals-extend-mundipharma-biosimilar-reach/
FDA approves Samsung/Merck & Co’s Herceptin biosimilarThe FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck Share XFDA approves Samsung/Merck & Co’s Herceptin biosimilarhttps://pharmaphorum.com/news/fda-approves-samsung-merck-cos-herceptin-biosimilar/
